Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
University of Michigan Rogel Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
NRG Oncology
National Cancer Institute (NCI)
OHSU Knight Cancer Institute